

Lorna Rodriguez-Rodriguez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10497402/publications.pdf>

Version: 2024-02-01

30
papers

2,864
citations

236925

25
h-index

454955

30
g-index

30
all docs

30
docs citations

30
times ranked

6435
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase I trial of daily subcutaneous SPL-108 injections in combination with paclitaxel in patients with platinum resistant CD44+ advanced ovarian epithelial cancer. <i>International Journal of Gynecological Cancer</i> , 2022, 32, 1032-1038.	2.5	4
2	Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer. <i>Case Reports in Oncology</i> , 2021, 14, 931-937.	0.7	8
3	CD44 in Ovarian Cancer Progression and Therapy Resistance—A Critical Role for STAT3. <i>Frontiers in Oncology</i> , 2020, 10, 589601.	2.8	39
4	Phase I trial of selenium plus chemotherapy in gynecologic cancers. <i>Gynecologic Oncology</i> , 2018, 150, 478-486.	1.4	27
5	Impact of body mass index on ovarian cancer survival varies by stage. <i>British Journal of Cancer</i> , 2017, 117, 282-289.	6.4	25
6	Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment. <i>International Journal of Molecular Sciences</i> , 2016, 17, 2113.	4.1	165
7	Racial/Ethnic Disparities in Ovarian Cancer Treatment and Survival. <i>Clinical Cancer Research</i> , 2016, 22, 5909-5914.	7.0	78
8	Precision targeted therapy of ovarian cancer. <i>Journal of Controlled Release</i> , 2016, 243, 250-268.	9.9	59
9	Role of Biomarkers in the Development of PARP Inhibitors. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S36679.	3.6	57
10	Emerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other Cancers. <i>Biomarkers in Cancer</i> , 2016, 8s1, BIC.S34417.	3.6	27
11	Precision Medicine: Implications for Science and Practice. <i>Journal of the American College of Surgeons</i> , 2016, 223, 433-439e1.	0.5	6
12	Impact of Chemotherapy Dosing on Ovarian Cancer Survival According to Body Mass Index. <i>JAMA Oncology</i> , 2015, 1, 737.	7.1	38
13	CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination. <i>Oncotarget</i> , 2015, 6, 26308-26321.	1.8	42
14	Tumor-Targeted Responsive Nanoparticle-Based Systems for Magnetic Resonance Imaging and Therapy. <i>Pharmaceutical Research</i> , 2014, 31, 3487-3502.	3.5	43
15	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
16	Nanotechnology approaches for personalized treatment of multidrug resistant cancers. <i>Advanced Drug Delivery Reviews</i> , 2013, 65, 1880-1895.	13.7	133
17	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
18	Targeted Nanomedicine for Suppression of CD44 and Simultaneous Cell Death Induction in Ovarian Cancer: An Optimal Delivery of siRNA and Anticancer Drug. <i>Clinical Cancer Research</i> , 2013, 19, 6193-6204.	7.0	149

#	ARTICLE	IF	CITATIONS
19	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. <i>Endocrine-Related Cancer</i> , 2013, 20, 251-262.	3.1	169
20	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
21	Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. <i>International Journal of Epidemiology</i> , 2013, 42, 579-589.	1.9	146
22	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
23	Identification of Function for CD44 Intracytoplasmic Domain (CD44-ICD). <i>Journal of Biological Chemistry</i> , 2012, 287, 18995-19007.	3.4	101
24	Two-in-one: combined targeted chemo and gene therapy for tumor suppression and prevention of metastases. <i>Nanomedicine</i> , 2012, 7, 185-197.	3.3	43
25	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. <i>PLoS ONE</i> , 2011, 6, e24987.	2.5	48
26	Healthy eating index and ovarian cancer risk. <i>Cancer Causes and Control</i> , 2011, 22, 563-571.	1.8	39
27	Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study. <i>BMC Women's Health</i> , 2011, 11, 40.	2.0	71
28	Multifunctional Tumor-Targeted Polymer-Peptide-Drug Delivery System for Treatment of Primary and Metastatic Cancers. <i>Pharmaceutical Research</i> , 2010, 27, 2296-2306.	3.5	47
29	Tumor Necrosis Factor- α Differentially Modulates CD44 Expression in Ovarian Cancer Cells. <i>Molecular Cancer Research</i> , 2006, 4, 511-520.	3.4	30
30	The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer. <i>Cancer Research</i> , 2005, 65, 6660-6667.	0.9	209